28 SEP 2006 00063827.DOC U.S. DEPARTMENT OF COMMERCE Form P.TO-1390 PATENT AND TRADEMARK OFFICE P25061 TRANSMITTAL LETTER TO THE UNITED STATES U.S. APPLICATION NO. (If known, see 37 CFR DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 10/551,549 PRIORITY DATE CLAIMED INTERNATIONAL FILING DATE INTERNATIONAL APPLICATION NO. PCT/JP2004/04704 31 March 2004 31 March 2003 TITLE OF INVENTION METHOD OF DISPAYING MOLECULE FUNCTION NETWORK APPLICANT(S) FOR DO/EO/US Akiko ITAI, Nobuo TOMIOKA, Makoto SHIGETAKA, and Miki FUKADA Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information. 1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. A This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (23) indicated below. 4. The US has been elected (PCT Article 31). 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. \square is attached hereto (required only if not communicated by the International Bureau). b. \square has been communicated by the International Bureau. c. I is not required, as the application was filed in the United States Receiving Office (RO/US). 6. An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)). a.

 is attached hereto. b. has been previously submitted under 35 U.S.C. 154 (d) (4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a.
 ☐ are attached hereto (required only if not communicated by the International Bureau). b. \square have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9.

An oath or declaration of the inventor(s) (35 U.S.C. .371(c)(4)). "Executed" 10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 22 below concern other document(s) or information included: 11. Assignee: Institute of Medicinal Molecular Design, Inc., of Tokyo, Japan 12.
An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 13. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 14. A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 15. An Application Data Sheet under 37 C.F.R. 1.76. 16. A substitute specification. A power of attorney and/or change of address letter. 18. A Figure of Drawing to be published: 1 19. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825. A second copy of the published international application under 35 U.S.C. 154 (d) (4). 21. 🔲 A second copy of the English language translation of the international of the international application under 35 U.S.C. 154 (d) (4). 22.
Other items or information: Cover Letter. PCT/DO/EO 905.